Human Amniotic Material Use in Post-Infarct Surgery to Mitigate Pathological Cardiac Outcomes

Abstract

Many different factors contribute to the development and progression of heart disease. Although substantial advancements have recently been established in the treatment and prevention of heart disease, it continues to produce one in every four deaths in the United States3. This indicates a growing need for treatment options for both cardiovascular disease and its related complications. Human Amniotic Material (HAM) presents a treatment option for the preservation of myocardial functionality as well as prevention of post-operative pericardial inflammation and development of altered electrical activity in the heart. Our research has shown that the application of HAM led to a significant reduction in the development of post-operative atrial fibrillation in humans undergoing cardiac surgery. Furthermore, HAM injection in an ischemic mouse model led to reduced pathological remodeling of the left ventricle, demonstrating its ability to improve the retention of cardiac function in ischemic tissues.